New and Improved Service

Posted:
26
August 2004

Claire Tucker, Head of Sales and Marketing

Richmond Pharmacology's (RPL's) highly successful business team has recently undergone a re-organisation to enhance the outstanding service we provide to our valued clients.Claire Tucker, Head of Sales and Marketing, commented:‘Our improved structure includes dedicated business Account Managers, specifically allocated to a particular client and able to guide them through the initial stages of introduction and study specific contract negotiation. These Account Managers continue to be at hand throughout as an additional point of contact until the study has reached its completion. As usual, our proficient Clinical Project Managers will co-ordinate the smooth day-to-day running of the study and will continue to work on a one to one basis with client teams. I am delighted with the new structure and the impact this is already having on our clients.’This framework has been introduced to ensure even better communication from initial contact through to close out, maintaining RPL's supportive and personal approach.Providing additional support for Phase II is our dedicated Phase II Department, see more on our patient studies page.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more